Status: Recruiting
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Participants needed: 50
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: Marzieh SalehiUpdated: Oct 5, 2026Locations: 2
Eligibility criteria
Male and female subjects aged 18-70 years (inclusive) at screening [+8]
History of, or any existing condition that, in the opinion of the investigator,... [+21]